Comparative Pharmacology
Head-to-head clinical analysis: AMLODIPINE MALEATE BENAZEPRIL HYDROCHLORIDE versus RENOTEC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMLODIPINE MALEATE BENAZEPRIL HYDROCHLORIDE versus RENOTEC.
AMLODIPINE MALEATE; BENAZEPRIL HYDROCHLORIDE vs RENOTEC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amlodipine is a dihydropyridine calcium channel blocker that inhibits the influx of calcium ions into vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced peripheral vascular resistance. Benazepril is an angiotensin-converting enzyme (ACE) inhibitor that prevents the conversion of angiotensin I to angiotensin II, resulting in vasodilation and reduced aldosterone secretion.
Renotec is a direct renin inhibitor that binds to the active site of renin, inhibiting the conversion of angiotensinogen to angiotensin I, thereby reducing angiotensin II levels and lowering blood pressure.
Initial: 2.5-5 mg amlodipine / 10-20 mg benazepril orally once daily, titrated to 10/40 mg once daily based on response.
Enalapril 5-40 mg orally once or twice daily; initial dose 5 mg once daily, titrate based on response.
None Documented
None Documented
Amlodipine: 30-50 h (terminal), allowing once-daily dosing; benazeprilat: 10-11 h (terminal), effective for 24 h.
Terminal elimination half-life is 12-15 hours; clinical context: supports once-daily dosing; half-life may be prolonged in renal impairment (creatinine clearance <30 mL/min).
Renal: Amlodipine 10% unchanged, benazeprilat (active metabolite) 50-60% in urine; biliary/fecal: amlodipine 20-25% as metabolites, benazeprilat 10-20% in feces.
Approximately 70% of the dose is excreted in urine as unchanged drug, and 20-30% via feces as metabolites; less than 5% is excreted unchanged in feces.
Category D/X
Category C
ACE Inhibitor
ACE Inhibitor